Literature DB >> 18972415

Sputum eosinophil apoptotic rate is positively correlated to exhaled nitric oxide in children.

Jennifer Pontin1,2, Morgan G Blaylock2, Garry M Walsh2, Stephen W Turner1.   

Abstract

RATIONALE FOR STUDY: Exhaled nitric oxide (FE(NO)), a potential biomarker for asthma, is positively correlated with eosinophilic airway inflammation. Eosinophil apoptotic rate (AR) may be increased by NO but the relationship between eosinophil AR and NO has not been studied in vivo. This study tested the hypothesis that eosinophil AR will be positively related to FE(NO).
METHODS: Children with and without asthma were recruited and participated in an assessment that included FE(NO) measurement, skin prick reactivity, spirometry, and sputum induction. The absolute sputum eosinophil count and eosinophil AR were determined by morphology under light microscope after staining.
RESULTS: There were 31 children recruited, mean age 11 years, 21 were asthmatic and 19 were boys. The median FE(NO) (range) was 15.6 parts per billion (3.1-102.6), 17 were atopic and the mean (SD)% FEV(1) was 85 (10)%. Sputum eosinophil AR was determined in 19 children (16 asthmatics), mean (SD) value 0.49 (0.13). There were positive relationships between eosinophil AR and FE(NO) (Spearman rho = 0.46, P = 0.046), eosinophil AR and % eosinophil count (Spearman rho = 0.45, P = 0.050) and also FE(NO) and % eosinophil count (Spearman rho = 0.49, P = 0.024).
CONCLUSION: There is a positive relationship between FE(NO) and eosinophil AR. Nitric oxide may be involved in regulation of eosinophil AR in the airways. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972415     DOI: 10.1002/ppul.20921

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  8 in total

Review 1.  Measures of asthma control.

Authors:  Christian Bime; Jessica Nguyen; Robert A Wise
Journal:  Curr Opin Pulm Med       Date:  2012-01       Impact factor: 3.155

2.  [Effects of artesunate on eosinophil apoptosis and expressions of Fas and Bcl-2 proteins in asthmatic mice].

Authors:  Ruiyin Wang; Jiangtao Lin; Jingru Wang; Chunxiao Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

Review 3.  Mitochondria signaling pathways in allergic asthma.

Authors:  Ling Qian; Entezar Mehrabi Nasab; Seyyede Masoume Athari; Seyyed Shamsadin Athari
Journal:  J Investig Med       Date:  2022-02-15       Impact factor: 3.235

Review 4.  Eosinophil apoptosis and clearance in asthma.

Authors:  Garry M Walsh
Journal:  J Cell Death       Date:  2013-04-17

5.  Induction of eosinophil apoptosis by hydrogen peroxide promotes the resolution of allergic inflammation.

Authors:  A C Reis; A L Alessandri; R M Athayde; D A Perez; J P Vago; T V Ávila; T P T Ferreira; A C S de Arantes; D de Sá Coutinho; M A Rachid; L P Sousa; M A Martins; G B Menezes; A G Rossi; M M Teixeira; V Pinho
Journal:  Cell Death Dis       Date:  2015-02-12       Impact factor: 8.469

6.  Nitric oxide-induced eosinophil apoptosis is dependent on mitochondrial permeability transition (mPT), JNK and oxidative stress: apoptosis is preceded but not mediated by early mPT-dependent JNK activation.

Authors:  Pinja Ilmarinen-Salo; Eeva Moilanen; Vuokko L Kinnula; Hannu Kankaanranta
Journal:  Respir Res       Date:  2012-08-24

7.  DP1 receptor signaling prevents the onset of intrinsic apoptosis in eosinophils and functions as a transcriptional modulator.

Authors:  Miriam Peinhaupt; David Roula; Anna Theiler; Miriam Sedej; Rudolf Schicho; Gunther Marsche; Eva M Sturm; Ian Sabroe; Marc E Rothenberg; Akos Heinemann
Journal:  J Leukoc Biol       Date:  2018-04-01       Impact factor: 4.962

8.  Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: a randomised trial (RAACENO).

Authors:  S Turner; S C Cotton; C D Emele; R Thomas; S Fielding; E A Gaillard; J C de Jongste; H Morgan; A R Neilson; J Norrie; M Pijnenburg; D Price; M Thomas
Journal:  Trials       Date:  2019-10-04       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.